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Background: Activated proximal tubular cells play an important role in renal fibrosis. We 
investigated whether sunitinib and a kidney-targeted conjugate of sunitinib were capable of 
attenuating fibrogenic events in tubulointerstitial fibrosis.
Methods: A kidney-targeted conjugate was prepared by linkage of a sunitinib analog (named 
17864) via a platinum-based linker to the kidney-specific carrier lysozyme. Pharmacological 
activity of 17864-lysozyme was evaluated in human kidney proximal tubular cells (HK-2); the 
capability of the kidney-directed conjugate to accumulate in the kidneys was studied in mice. 
Potential antifibrotic effects of a single-dose treatment were evaluated in the unilateral ureteral 
obstruction (UUO) model in mice.
Results: The 17864-lysozyme conjugate and its metabolites strongly inhibited tyrosine kinase 
activity. Upon intravenous injection, 17864-lysozyme rapidly accumulated in the kidneys and 
provided sustained renal drug levels for up to 3 days after a single dose. Renal drug level area 
under the curve was increased 28-fold versus an equimolar dose of sunitinib malate. Daily 
treatment of UUO mice with a high dose of sunitinib malate (50 mg/kg) resulted in antifibrotic 
responses, but also induced drug-related toxicity. A single dose of 17864-lysozyme (equivalent 
to 1.8 mg/kg sunitinib) was safe but showed no antifibrotic effects.
Conclusion: Multikinase inhibitors like sunitinib can be of benefit in the treatment of fibrotic 
diseases, provided that their safety can be improved by strategies as presented in this paper, 
and sustained renal levels can be achieved.
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Introduction
Progression of untreated kidney diseases results in tubulointerstitial fibrosis, eventu-
ally leading to end-stage renal disease.1,2 Activation of proximal tubular cells is an 
important step in the pathogenesis of tubulointerstitial fibrosis.3 Activated proximal 
tubular cells secrete chemotactic proteins that attract macrophages and other immune 
cells.4 Tubular cell activation also leads to epithelial-to-mesenchymal transition 
(EMT) of proximal tubular epithelial cells and excessive production of extracellular 
matrix (ECM) components. As a result, normal tissue is replaced by scar tissue and 
the kidney function is decreased.1,5,6 Since currently used drugs such as angiotensin-
converting enzyme inhibitors and angiotensin II receptor type 1 antagonists are only 
partially effective,7,8 there is an urgent need for drugs that halt or even reverse the 
profibrotic processes.
Multiple signaling pathways are involved in the activation of tubular cells in tubu-
lointerstitial fibrosis.1,2 Simultaneous inhibition of these cascades by a   multitargeted 
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kinase inhibitor therefore seems an attractive strategy. 
  Sunitinib is a multitargeted tyrosine kinase inhibitor approved 
for the treatment of metastatic renal-cell carcinoma and 
gastrointestinal stromal tumors and currently also under 
investigation for the treatment of other types of cancer.9–11 
Compared with other kinase inhibitors, sunitinib interacts 
with high affinity (ie, Kd , 100 nM) with a broad range 
of kinases,12 including the platelet-derived growth factor 
receptors (PDGFR) PDGFR-α and -β and the vascular 
endothelial growth factor receptors (VEGFR) VEGFR-1 
and −2.9,10 Overactivation of the PDGFR kinase pathway 
has been associated with the development of renal fibrosis 
by stimulating the proliferation, migration, and survival of 
myofibroblasts.13,14 The VEGFR kinase pathway has also 
been linked to renal fibrosis, although less clearly than the 
PDGFR kinase pathway.15,16 Sunitinib has not yet been 
investigated for the treatment of renal fibrosis, but has suc-
cessfully been used to treat experimental liver fibrosis.17 We 
now propose to use a renally targeted sunitinib analog as an 
antifibrotic treatment in kidney fibrosis.
One main concern when using a multitargeted kinase 
inhibitor for the treatment of renal fibrosis is the possible 
increased risk of side effects compared with more selec-
tive kinase inhibitors.18 Sunitinib has been associated with 
many side effects, including severe cutaneous toxicities and 
cardiotoxicity.11,19–22 To avoid these side effects, targeted 
delivery of sunitinib to the target cells, ie, the proximal 
  tubular cells of the kidneys, is a comprehensive approach. We 
have shown that small-molecule inhibitors can be   delivered to 
the kidney by conjugation to lysozyme,23–25 a low molecular 
weight protein that is rapidly filtered through the glomeruli 
of the kidneys and subsequently taken up at the apical mem-
brane of proximal tubular cells via megalin receptor-mediated 
internalization.26
Since sunitinib does not contain functional groups 
such as hydroxyl or primary amino groups that can be 
used for the coupling to lysozyme, we designed a sunitinib 
derivative that can be linked to lysozyme via the platinum 
(II)-based Universal Linkage SystemTM (ULS) (Kreatech 
  Diagnostics, Amsterdam, The Netherlands). This platinum 
linker forms stable coordinative bonds with pyridyl groups or 
other types of aromatic nitrogens, and can be conjugated to 
thiol groups in proteinaceous carriers.27 One of the important 
properties of conjugates prepared with this type of linker is 
the prolonged retention of the delivered drug inside the target 
cells (ie, several days), as was demonstrated in pharmacoki-
netic studies in rats. Upon intravenous administration, the 
  majority of the targeted drug persisted in the designated cells 
in the ULS-bound form.25,28 In the current study, we therefore 
designed a sunitinib analog which retained its activity in 
the ULS-bound form, and thus could display its activity as 
a platinum conjugate upon delivery in the proximal tubular 
cells of the kidneys.
Sunitinib is a type I adenosine triphosphate (ATP)-
competitive kinase inhibitor that exerts its effects on target 
kinases by binding in and around the adenine region of the 
ATP-binding pocket.29 Structural binding studies of sunitinib 
have revealed that the oxindole moiety of sunitinib is local-
ized deep in the ATP-binding pocket of target kinases, where 
it is bound to the adenine region via hydrophobic interactions, 
while the N-2-(diethylamino)ethylene side chain is exposed 
outwards.30,31 We recently demonstrated that this group can be 
replaced by a pyridyl side chain and that platinum conjugates 
of such a sunitinib analog retain activity.32 Figure 1 shows 
the chemical structure of this newly developed sunitinib 
analog called 17864. In the current study we investigated 
the coupling of 17864-ULS to the renal carrier lysozyme, as 
well as the in vitro capability of platinum-bound 17864 to 
inhibit kinase activity. The in vivo accumulation of 17864-
ULS-lysozyme in the kidneys was studied after intravenous 
administration to mice. We also investigated the antifibrotic 
effects of sunitinib and 17864-ULS-lysozyme in mice with 
unilateral ureteral obstruction (UUO)-induced tubulointer-
stitial fibrosis.
Materials and methods
Materials and chemicals
The sunitinib analog 17864 was synthesized accord-
ing to Sun et al by Vichem Chemie (Budapest, Hun-
gary).33   Sunitinib malate was purchased from Sequoi 
Research Products (Pangbourne, UK). The ULS cis-
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Figure 1 Structures of the multitargeted tyrosine kinase inhibitor sunitinib (A) and 
the ULS-linkable sunitinib derivative 17864 (B). The aliphatic N-2-(diethylamino)
ethylene sidechain of sunitinib has been replaced by a N-4-methylpyridine side chain 
(red). When binding to target kinases, the oxindole moiety (blue) of the drug is 
located in the adenine region of the ATP-binding pocket, while the N-2-(diethylamino)
ethylene moiety or N-4-methylpyridine are protruding outwards.
Abbreviation: ATP, adenosine triphosphate.
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[Pt(ethylenediamine)nitrate-chloride] was synthesized from 
cis-[Pt(ethylenediamine)dichloride] as described elsewhere.34 
Lysozyme from hen egg white was purchased from Fluka 
(Zwijndrecht, The   Netherlands). The TaqMan® Universal PCR 
Master Mix, No   AmpErase® UNG, and The TagMan® Gene 
Expression Assays Mm00446973_m1, Mm00435860_m1, 
Mm00483888_m1, Mm01256734_m1, and Mm00441242_
m1 for the detection of, respectively, TATA-binding protein 
(TBP), plasminogen activator inhibitor-1 (PAI-1), Collagen 
1A2, fibronectin, and monocyte chemotactic protein-1 (MCP-
1) were purchased from Applied Biosystems   (Nieuwerkerk 
aan den IJssel, The Netherlands). Goat anti-mouse megalin 
(P-20), rabbit anti-mouse p-PDGFR-β, and rabbit anti-mouse 
vimentin polyclonal antibodies were purchased from Santa 
Cruz (Heidelberg, Germany). Rabbit anti-hen egg white 
lysozyme polyclonal antibody was purchased from   Millipore 
  (Amsterdam, The Netherlands). Alexa fluor 488 donkey 
anti-goat and Alexa fluor 647 donkey anti-rabbit second-
ary antibodies were purchased from Invitrogen (Breda, The 
Netherlands). Rabbit anti-mouse β-actin polyclonal antibody 
and horseradish peroxidase (HRP)-conjugated goat anti-rabbit 
secondary antibody were purchased from Cell Signaling 
Technology (Leiden, The Netherlands). Mouse anti-human 
phosphotyrosine (PY20) (HRP) monoclonal antibody, rab-
bit anti-mouse α-smooth muscle actin (SMA) antibody, and 
rabbit anti-mouse collagen type IV antibody were purchased 
from Abcam (Cambridge, UK). BrightVision HRP-conjugated 
goat anti-rabbit secondary antibody was purchased from 
Immunologic (Duiven, The Netherlands).
Synthesis of 17864-ULS-lysozyme
Sunitinib analog 17864 was coupled to the platinum (II)-
based linker ULS by incubating equimolar amounts (ie, 
107 µmol) of 17864 and ULS in 9 mL dimethylformamide 
for 4 hours at 37°C. To confirm the formation of the 17864-
ULS 1:1 adduct, the final product was analyzed with mass 
spectrometry and 195Pt-nuclear magnetic resonance (NMR). 
To introduce thiol groups onto the protein’s surface that 
could react with the platinum linker, lysozyme (10 mg/mL 
in phosphate-buffered saline [PBS]) was reacted with a 3× 
molar excess of BOC-L-methionine N-hydroxysuccinimide 
ester (50 mg/mL in dimethyl sulfoxide [DMSO]) for 1 hour 
at ambient temperature. Purification of the product was 
performed by dialysis against water. Methionine-lysozyme 
was lyophilized and characterized by matrix-assisted laser 
desorption-ionization time-of-flight (MALDI-TOF) mass 
spectrometry. Lastly, methionine-lysozyme was incu-
bated with a 3× molar excess of 17864-ULS in 0.02 M 
tricine/sodium nitrate buffer pH 8.5 overnight at 37°C. 
The 17864-ULS-lysozyme conjugate obtained was puri-
fied by dialysis at 4°C against 10% dimethyl sulfoxide in 
demineralized water, followed by extensive dialysis against 
demineralized water. The purified conjugate was lyophilized 
and stored at −20°C until further use.
Characterization of 17864-ULS-lysozyme
For the characterization of 17864-ULS-lysozyme an 8 mg/mL 
stock solution in water was prepared and subsequently filtered 
through a 0.2 µm filter. The concentrations of 17864-ULS 
and lysozyme in this solution were measured to establish 
the drug/carrier ratio in the final product. Lysozyme was 
measured using the Micro BCATM Protein Assay Kit (Thermo 
Scientific, Etten-Leur, The Netherlands). For the analysis 
of the amount of 17864-ULS conjugated to lysozyme, the 
drug was displaced from the linker with an excess of potas-
sium thiocyanate (KSCN) and the concentrations of liber-
ated 17864 were determined with high-performance liquid 
chromatography. Briefly, the stock solution was diluted six 
times in a mixture of 50% PBS, 50% acetonitrile (ACN), and 
0.05% trifluoroacetic acid (TFA) containing a final concen-
tration of 0.5 M KSCN and incubated for 24 hours at 80°C. 
After reaching ambient temperature, 200 µL ACN with 0.1% 
TFA was added to the samples. The samples were mixed by 
vortexing and centrifuged for 4 minutes at 19,500 g. Fifty 
microliters of the supernatants were injected in a reversed 
phase high-performance liquid chromatography system 
consisting of a Waters 2695 separations module, a Waters 
2487 dual λ absorbance detector and a Waters SunFireTM 
C18 column (4.6 × 150 mm, 5 µm particle size) (Waters, 
Milford, MA). Empower 2 software (Waters) was used for 
data recording. The column and sample temperature were 
maintained at 30°C and 20°C, respectively. A gradient was 
used with eluent A consisting of 5% ACN/95% water/0.1% 
TFA (w/w/w) and eluent B consisting of ACN/0.1% TFA 
(w/w). The composition of the mobile phase was linearly 
changed from 100% to 20% eluent A in 25 minutes using 
a flow rate of 1 mL/minute. Sunitinib analog 17864 was 
detected at 431 nm.
Cell culture
The immortalized human renal proximal tubule epithelial 
cell line (HK-2) (American Type Culture Collection, LGC 
  Standards, Teddington, UK) was cultured in Dulbecco’s 
  Modified Eagle’s Medium containing 3.7 g/L sodium 
  bicarbonate, 1.0 g/L glucose, supplemented with 10% (v/v) fetal 
bovine serum, penicillin (100 U/L), streptomycin (100 µg/mL), 
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and amphotericin B (0.25 µg/mL) at 37°C with 5% CO2 in 
humidified air. All cell culture-related media were obtained 
from PAA Laboratories GmbH (Pasching, Austria).
In vitro inhibition of tyrosine  
kinase activity
The inhibitory effects of 17864-ULS-lysozyme on the 
  phosphorylation of tyrosine kinases were studied after 
internalization in HK-2 cells seeded onto 96-well plates 
(1.5 × 104 cells/well). Cells were serum-starved overnight 
and subsequently incubated with 10 µM 17864, 17864-ULS, 
methionine-modified lysozyme, 17864-ULS-lysozyme, or 
sunitinib malate. After 24 hours, cells were washed thrice 
with PBS and lysed with mammalian protein extraction 
reagent containing protease- and phosphatase-inhibitors. 
Protein concentrations of the lysates were determined 
using the micro bicinchoninic acid (BCA)™ assay (Pierce 
  Biotechnology, Thermo Scientific, Rockford, IL).
The phosphorylation activity of kinases present in the 
lysates and inhibition by the intracellular accumulated 
inhibitors was investigated by addition of an equal volume of 
10 µM ATP in Abl kinase assay buffer (consisting of 50 mM 
2-amino-2-(hydroxymethyl)-1,3-propanediol (Tris)-HCl [pH 
7.5], 10 mM MgCl2, 1 mM ethyleneglycoltetraacetic acid, 
2 mM dithiothreitol (DTT), and 0.01% Brij-35). After incu-
bation at 37°C for 60 minutes, the reaction was terminated 
by adding reducing sample buffer (Invitrogen) containing a 
final concentration of 40 mM DTT and 0.1% (w/v) sodium 
dodecyl sulfate (SDS). Total protein (10 µg) was separated 
by SDS-PAGE using a NuPAGE® 4%–12% Bis-Tris precast 
gel and NuPAGE® 3-(N-morpholino)propanesulfonic acid 
(MOPS)-SDS running buffer (Invitrogen). Proteins were 
transferred onto a 0.45 µm Immobilon™-P polyvinylidene 
fluoride membrane (Millipore) by wet blotting. The transfer 
buffer consisted of 25 mM Tris, 192 mM glycine, and 10% 
methanol (v/v) and a transfer voltage was used of 100 V for 
1 hour. After 1 hour blocking at room temperature with 3% 
(w/v) bovine serum albumin (BSA) in Tris-buffered saline 
(TBS) with 0.1% (v/v) Tween-20 (TBS with 0.1% [v/v]; 
Tween-20 will be further referred to as TBS/T), the membrane 
was incubated for 1 hour at room temperature with mouse 
anti-human phosphotyrosine (PY20) (HRP) monoclonal 
antibody (1:500) in 3% BSA in TBS/T. The membrane was 
washed with TBS/T and proteins were visualized using the 
SuperSignal® West Femto Maximum Sensitivity Substrate 
Kit (Thermo Scientific). Band densities were determined on 
a Gel Doc XRS Imaging system with Quantity One analysis 
software (Bio-Rad, Hercules, CA).
The inhibitory effects of 17864, 17864-ULS, and 17864-
ULS-lysozyme were also studied by spiking the inhibitors 
to lysates of serum-starved control HK-2 cells. 0.1 mg/mL 
HK-2 cell lysates were preincubated with 2 µM of the com-
pounds for 30 minutes at room temperature after which the 
cell lysates were stimulated with 1 µM ATP and processed 
as described above.
In vitro cytotoxicity
HK-2 cells were seeded (4 × 103 cells/well in a total volume of 
100 µL complete medium) in 96-well plates 24 hours prior to 
addition of the samples. Cell were then incubated for 24 hours 
with methionine-lysozyme, sunitinib malate, and 17864-ULS-
lysozyme (n = 6 for all samples) up to a concentration of 50 µM 
and under normal culture conditions. Untreated HK-2 cells 
were used as a control. The cytotoxicity of the samples was 
established using the sulforhodamine B (SRB) colorimetric 
assay.35 After incubation, HK-2 cells were fixed in situ by 
incubation with 50 µL/well 12.5% (w/v) trichloroacetic acid 
in demineralized water for 1.5 hours at 4°C. Supernatants 
were removed from the wells and the cells were washed four 
times with normal water and subsequently air-dried. Staining 
was performed by incubation of the cells with 100 µL/well 
0.4% (w/v) SRB in 1% acetic acid in demineralized water 
for 15 minutes at room temperature, under shaking. The SRB 
solution was removed from the wells and the cells were washed 
four times with 1% (v/v) acetic acid in demineralized water. 
After air-drying, cells were incubated with 200 µL/well 10 mM 
Trizma® base (Sigma-Aldrich, St Louis, MO) in demineralized 
water for 15 minutes at room temperature, under shaking. The 
optical density was measured at 550 nm. Nonlinear regression 
curve-fitting with GraphPad Prism software (v 5; GraphPad 
Software Inc, San Diego, CA) was used to calculate the half 
maximal inhibitory concentration of sunitinib malate.
Animal experiments
All in vivo experiments were performed in normal male 
C57BI/6 J mice obtained from Harlan (Zeist, The   Netherlands). 
Mice were ordered with a body weight of 13–25 g and were 
used within 4 weeks after arrival. The mice were housed in 
cages in a 12-hour light and 12-hour dark cycle and given food 
and water ad libitum. Experimental protocols for pharmacoki-
netic and efficacy studies were approved by the animal ethics 
committee of the Utrecht University, The Netherlands.
Pharmacokinetic studies
The pharmacokinetics of 17864-ULS-lysozyme was 
  studied in mice and compared with the pharmacokinetics of 
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  sunitinib malate. Mice received a single intravenous   injection 
of either 17864-ULS-lysozyme (n = 17; 20 mg/kg) or an 
equimolar dose of sunitinib malate (n = 15; 1.7 µmol/kg, 
0.9 mg/kg). At 1 minute after administration of the com-
pounds, a blood sample was taken via a cheek puncture. 
Animals were sacrificed at the indicated time points. Blood 
samples were collected, centrifuged twice at 5500 g for 
15 minutes at 4°C and stored at −80°C until further analysis 
as described below. Kidneys were removed and stored at 
−80°C until further processing as described below. Plasma 
and renal drug levels were expressed as a percentage of the 
injected dose. The calculation of the percentage of the dose 
in the total plasma volume was based on an average plasma 
volume of 0.05 mL/g of mouse body weight.36 Absorption 
and elimination half-lives, distribution volumes, and areas 
under the curves were calculated by curve-fitting with a two-
compartment model with Multifit pharmacokinetic software 
(University of Groningen, Groningen, The Netherlands).
Immunostaining of kidney sections
Uptake of 17864-ULS-lysozyme in proximal tubular cells 
was investigated by immunostaining of the carrier part, ie, 
chicken egg-white lysozyme, and the megalin receptor which 
is expressed on proximal tubular cells. Paraffin-embedded 
kidney sections of 4 µm were deparaffinized in xylene and 
hydrated in a graded series of alcohol baths. Enzyme pretreat-
ment was performed in Tris (4.84 g/L)/EDTA (372 mg/L) 
buffer with pH 9. Sections were subsequently incubated with 
goat anti-mouse megalin primary antibody (1 hour), Alexa 
fluor 488 donkey anti-goat secondary antibody (30 minutes), 
rabbit anti-hen egg white lysozyme primary antibody 
(1 hour), and Alexa fluor 647 donkey anti-rabbit secondary 
antibody (30 minutes). Antibodies were diluted in PBS with 
1% BSA and 1% azide. Sections were washed with PBS 
containing 0.05% tween-20 (PBS/0.05T). Stained sections 
were analyzed using confocal laser scanning microscopy.
Liquid chromatography-tandem  
mass spectrometry (LC-MS/MS)  
analysis of sunitinib
Plasma and renal sunitinib concentrations were measured 
according to the following protocol. Calibration standards 
were prepared in a concentration range of 10 ng/mL–1 µg/mL 
sunitinib malate in blank human plasma and 10–500 ng/mL 
in blank kidney homogenate. Plasma samples collected at 
1 minute after administration of sunitinib malate were diluted 
two times with blank human plasma; other samples were 
processed undiluted. Blank kidney homogenate was prepared 
by homogenizing kidneys of non-treated C57BI/6 J mice in 
4% (w/v) BSA in demineralized water in a final concentra-
tion of 0.1 g tissue/mL. The kidney homogenates of the mice 
injected with sunitinib malate were prepared in the same 
manner. Blank human plasma and kidney homogenate were 
used as negative control.
A 100 µL sample was spiked with 50 µL  of  a 
4-  hydroxybenzophenone internal standard solution 
(50 µg/mL in methanol). Sunitinib was extracted from the 
biological matrices (ie, plasma and kidney tissue) using 
2 × 1 mL tert-butyl methyl ether (TBME). After addition 
of TBME, samples were mixed vigorously and centrifuged 
for 5 minutes at 7500 g. The aqueous layers were frozen in 
a bath of ethanol with dry ice and the TBME layers were 
collected. Evaporation of the TBME (in a rotational vacuum 
concentrator [RVC 2-25; Martin Christ GMBH, Osterode 
am Harz, Germany] for 45 minutes at 45°C) was followed 
by reconstitution of the samples in 100 µL ACN contain-
ing 0.1% TFA. After 3 minutes centrifugation at 21,000 g, 
supernatants were diluted three times with demineralized 
water before analysis with LC-MS/MS. The LC-MS/MS 
equipment and general MS/MS setting were reported previ-
ously by   Sparidans et al.37 Partial-loop injections (2 µL) were 
made on an Aquity UPLC® BEH C18 column (30 × 2.1 mm, 
dp = 1.7 µm, Waters, Milford, MA) with the corresponding 
VanGuard pre-column (Waters, 5 × 2.1 mm, dp = 1.7 µm). 
The column temperature was maintained at 40°C and the 
autosampler sample rack compartment was maintained at 
4°C. The eluent comprised a mixture of two solvents: 0.1% 
(v/v) formic acid in water (A) and methanol (B), pumped 
at 0.5 mL/minute. The amount of solvent B was increased 
from 20 to 60% during 2 minutes after injection, followed by 
flushing the column for 0.5 minutes with 90% methanol, and 
reconditioning the column at 20% methanol for 1.5 minutes. 
The whole   eluate was transferred into the electrospray ioniza-
tion source, starting at 0.7 minutes after injection by switch-
ing the MS inlet valve. The selected reaction monitoring 
mode was used with argon as the collision gas at 1.5 mTorr. 
Dwell times were 0.2 seconds for sunitinib and 0.1 second 
for the internal standard. The tube lens offset was 92 V for 
sunitinib and 100 V for the internal standard. Sunitinib was 
monitored at m/z 399.24 → 283.15 at −24 V collision energy; 
the internal standard at m/z 199.00 → 121.00 at −15 V .
LC-MS/MS analysis of 17864-ULS-
lysozyme
Total 17864 (ie, the combined level of 17864-ULS-
lysozyme + 17864-ULS + released 17864) and free 17864 (ie, 
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released 17864 levels) were measured in plasma and kidney 
homogenate. Analyses were performed using the sunitinib 
malate protocol with minor modifications.
For the measurement of the total 17864 concentrations in 
plasma and kidneys, samples spiked with the internal standard 
were incubated at 80°C for 24 hours with an   equivolume of 
1 M KSCN in PBS to displace platinum-bound 17864 from 
the ULS linker. Next, 17864 was extracted with TBME. 
Plasma samples collected at 1 minute after administration of 
17864-ULS-lysozyme were diluted three times with blank 
human plasma, all other samples were processed undiluted.
For the 17864 LC-MS/MS analysis, the same equip-
ment and column were used as for sunitinib, with some 
modifications in the conditions. The amount of solvent B 
was increased from 10% to 70% during the 3 minutes after 
injection, followed by flushing the column for 0.5 minutes 
with 70% methanol, and reconditioning the column with 10% 
methanol for 1.5 minutes. The whole eluate was transferred 
into the electrospray ionization source, starting at 0.8 min-
utes after injection by switching the MS inlet valve, until 
4 minutes after injection. The selected reaction monitoring 
mode was used with argon as the collision gas at 2.0 mTorr 
and 40 millisecond dwell times. Sunitinib analog 17864 was 
monitored at m/z 373.14 → 239.17 at −18 V collision energy 
and the tube lens offset was 108 V .
Antifibrotic effects of sunitinib  
and 17864-ULS-lysozyme  
in UUO-induced fibrosis
Antifibrotic effects of sunitinib malate and 17864-ULS-
lysozyme have been studied in mice with UUO-induced tubu-
lointerstitial fibrosis. Surgically induced ureteral obstruction 
was performed according to the following protocol. Under 
isoflurane anesthesia (3% in 100% O2; 1 L/minute) the ureter 
of the left kidney was ligated at two places with silk (5–0). 
Mice were sacrificed after 3 days’ ureteral obstruction.
Mice were randomly divided into two control groups 
(n = 6 per group) and three treatment groups (n = 7 per 
group). The first control group consisted of normal mice 
without UUO-induced tubulointerstitial fibrosis and the 
second control group of mice with UUO-induced tubu-
lointerstitial fibrosis without treatment. In the treatment 
groups, mice with UUO-induced renal fibrosis were treated 
with a single intravenous injection of 40 mg/kg 17864-
ULS-lysozyme (corresponding to 3.4 µmol/kg 17864), an 
equimolar single intravenous injection of sunitinib malate 
(3.4 µmol/kg; 1.8 mg/kg) or three daily intraperitoneal injec-
tions of 50 mg/kg sunitinib malate (94 µmol/kg).
Western blot analysis
The activation of PDGFR-β after 3 days ureteral obstruction 
and the inhibitory effects of the intrinsically active 17864-
ULS-lysozyme conjugate on the activated PDGFR-β levels 
were detected in the renal cortex by Western blot analysis 
of phosphorylated PDGFR-β (p-PDGFR-β). Cortex homo-
genates were prepared by homogenizing a small part of the 
cortex in 400 µL RIPA buffer supplemented with protease- 
and phosphatase inhibitors and EDTA. After measuring the 
protein content of the samples with the Micro BCATM Protein 
Assay Kit (Thermo Scientific), 7 µL 4 × SDS-containing 
loading buffer was added to an aliquot of the samples corre-
sponding with 50 µg protein. Demineralized water was added 
to adjust the total volume of the samples to 30 µL and the 
samples were heated for 7 minutes at 95°C. Proteins were sep-
arated by SDS-PAGE in a similar manner as described above 
for the investigation of the in vitro activity of the   conjugate. 
After transferring the proteins onto a polyvinylidene fluoride 
membrane, the part containing the proteins with a molecular 
size .100 kDa was used for the detection of p-PDGFR-β 
and the part of the membrane containing the proteins with 
a molecular size ,100 kDa for the detection of β-actin. 
Membranes were blocked for 1 hour at room temperature in 
blocking buffer (ie, 5% nonfat dry milk in TBS/T) before 
overnight incubation at 4°C with the primary antibodies (ie, 
rabbit anti-mouse p-PDGFR-β (Tyr 740) (1:200) or rabbit 
anti-mouse β-actin (1:1000) polyclonal antibody) in TBS/T 
with 5% (w/v) BSA. Next, membranes were incubated for 
1 hour at room temperature with HRP-conjugated goat anti-
rabbit secondary antibody (1:1000 in TBS/T with 5% (w/v) 
nonfat dry milk), followed by the detection of p-PDGFR-β 
and β-actin using the SuperSignal® West Femto Maximum 
Sensitivity Substrate Kit (Thermo Scientific). Wash steps 
were performed with TBS/T.
Gene expression analysis
The inhibitory effects of 17864-ULS-lysozyme on the mRNA 
expression of collagen 1A2, PAI-1, fibronectin, and MCP-1 in 
the whole kidneys and the cortex have been analyzed by quan-
titative reverse transcription polymerase chain reaction (qRT-
PCR). Total RNA was isolated from .1.8 mg tissue using the 
RNeasy KIT from QIAGEN (Venlo, The Netherlands). The 
RNA content in the samples was measured by UV-detection 
with the NanoDrop 1000 (NanoDrop, Wilmington, DE). For 
all samples, the ratio between the absorbance at 260 nm and 
280 nm was higher than 1.8, indicating that the RNA samples 
were not contaminated with DNA. After RNA extraction, 
300 ng of RNA was used for the synthesis of complementary 
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DNA (cDNA). For the synthesis of cDNA the RevertAid™ 
Premium First Strand cDNA Synthesis Kit from Fermentas 
(Sankt Leon-Rot,   Germany) was used. The obtained cDNA 
samples were diluted ten times with Milli-Q water (Millipore) 
before use. For the qRT-PCR analyses, each sample consisted 
of 2.5 µL 10 times diluted cDNA, 0.625 µL TagMan® Gene 
Expression Assay, 6.25 µL TaqMan®   Universal PCR Master 
Mix (both from Applied Biosystems), and 3.125 µL Milli-Q 
water. The analyses were performed using the Applied Bio-
systems ABI PRISM® 7900HT Sequence Detection System 
(Nieuwerkerk aan den IJssel, The Netherlands). Sequence 
Detection System Software (v 2.2) was used for data analysis. 
Statistical analysis of the results was performed using one-way 
analysis of variance (ANOVA), with P , 0.05 as the minimal 
level of significance.
Immunostaining of fibrotic  
markers in kidney sections
Paraffin-embedded kidney sections of 3 µm were   deparaffinized 
in xylene and hydrated in a graded series of alcohol baths. 
After 15 minutes incubation in blocking buffer   (consisting 
of 1 part hydrogen peroxide 30% and 19 parts of a   solution 
containing 8.32 g/L citric acid, 21.52 g/L disodium   hydrogen 
phosphate dehydrate, and 2 g/L sodium azide, pH 5.8), kidney 
sections were boiled for 15 minutes in 10 mM citrate buffer 
pH 6.0 (for collagen IV and vimentin) or Tris/EDTA buf-
fer (containing 4.84 g/L Tris and 372 mg/L EDTA) pH 9.0 
(for α-SMA). Back at room temperature, kidney sections 
were washed with PBS   containing 0.05% (v/v) Tween-20® 
(Sigma-Aldrich) (PBS/0.05T) and incubated for 1 hour with 
the primary antibodies at room   temperature. All primary anti-
bodies were diluted in PBS with 1% (w/v) BSA; rabbit anti-
mouse α-SMA 1:400, rabbit anti-mouse collagen IV 1:400, 
and rabbit anti-mouse vimentin 1:200. Kidney sections were 
subsequently washed with PBS/0.05T, incubated for 30 min-
utes at room temperature with undiluted HRP-conjugated 
BrightVision goat anti-rabbit secondary antibody, washed 
with PBS, and incubated for 10 minutes with 3,3-diamin-
obenzidine (DAB) in the presence of hydrogen peroxide (to 
1 mL, 6 g/L DAB in demineralized water, 9 mL phosphate/
citrate buffer, pH 9.0, and 10 µL hydrogen peroxide 30% were 
added). Nuclei were stained by washing the kidney sections 
three times with demineralized water, placing the sections 
for 10–15 seconds in undiluted hematoxylin solution (Gill’s 
No 2), and rinsing them with normal tap water for at least 
10 minutes. Kidney sections were dehydrated in a graded 
series of alcohol baths and xylene, mounted, and analyzed 
using light microscopy.
Results and discussion
Synthesis and characterization  
of 17864-ULS-lysozyme
Figure 2 shows the reaction scheme followed for the prepara-
tion of 17864-ULS-lysozyme. The successful formation of a 
coordinative bond between the platinum (II) linker and the 
aromatic nitrogen of the pyridine ring in 17864 was proven 
by mass spectrometry and 195Pt-NMR analysis. 195Pt-NMR 
analysis showed a peak at −2493 ppm which, as has been 
demonstrated for different drug-ULS-carrier conjugates,38,39 
is characteristic for a Pt-N3 coordination. The fact that the 
sunitinib analog SU6668 (ie, [Z]-3-[2,4-dimethyl-5-([2-
oxoindolin-3-ylidene]methyl)-1H-pyrrol-3-yl]propanoic acid) 
cannot be coordinated to the ULS linker indirectly proves that 
the ULS linker in 17864-ULS is coordinated to the pyridine 
nitrogen in 17864. Mass spectrometry demonstrated that the 
reaction of 17864 to ULS yielded 80% of the desired 17864-
ULS 1:1 adduct (detected ESI+ MS peaks: m/z 663 of [M]+, 
m/z 626 of [M-Cl−-H+]+, and m/z 681 of [M+OH−+ H +]+; 
M = 17864-ULS with chloride ion as second ligand attached 
to the platinum atom (Figure 2)). Besides the 1:1 adduct, 
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the product also contained 14% of the dimeric adduct, ie, 
(17864)2-ULS. This disubstituted drug-ULS-drug adduct can-
not react with the renal carrier protein and was removed from 
the product in the final dialysis step of 17864-ULS-lysozyme. 
Thiol groups were introduced on the surface of lysozyme by 
modification of the carrier protein with methionine residues. 
MALDI-TOF mass spectrometric analysis of the modified 
lysozyme yielded peaks at m/z 14,539, 14,772, 15,006, and 
15,238, corresponding to BOC-methionine-lysozyme with, 
respectively, one, two, three, and four methionine residues 
attached to the renal carrier protein (theoretical masses: 
14,537, 14,769, 15,000, and 15,231 Da, respectively). This 
allowed the conjugation of 17864-ULS at a 1.2:1 coupling 
ratio under the applied conditions with a 3:1 synthesis ratio 
of drug-ULS: lysozyme.
In vitro activity of 17864-ULS-lysozyme 
after uptake in HK-2 cells
We investigated the multikinase inhibitory effects of 
17864-ULS-lysozyme after internalization and intracellular 
processing by HK-2 cells by analyzing its potency to reduce 
the level of phosphorylation activity of tyrosine kinases. 
Figure 3A shows the anti-phosphotyrosine Western blot of 
HK-2 cells exposed to 10 µM of 17864, 17864-ULS, methio-
nine-lysozyme, 17864-ULS-lysozyme, and sunitinib malate, 
respectively. Both sunitinib and 17864-ULS-lysozyme 
strongly inhibited multiple kinases, as can be deduced from 
the strong reduction in tyrosine-phosphorylated proteins. 
The inhibitory effects of 17864-ULS were almost as strong 
as the inhibitory effects observed with sunitinib. Unexpect-
edly, unmodified 17864 did not reduce the phosphorylation of 
tyrosine kinases in this experimental set-up. We conducted an 
additional experiment, in which the compounds were spiked 
directly into the cell lysate. Differences in uptake and cytoso-
lic delivery of the compounds were thereby avoided. Again, 
unmodified 17864 showed only a minor reduction in tyrosine 
phosphorylation, while a strong inhibition was observed 
with 2 µM of both 17864-ULS and 17864-ULS-lysozyme 
 ( Figure 3B). Of note, 17864 showed proper inhibitory activity 
against recombinant PDGFR-β, with a similar half maximal 
inhibitory concentration as sunitinib and 17864-ULS.32 
We therefore believe that the lower activity in the present 
assays relates to differences in selectivity profiles between 
the compounds versus other kinases than the ones tested so 
far. Despite the relatively lower activity of 17864 itself, our 
results demonstrate that platinum-bound 17864 still exerts 
its multikinase inhibitor effects and that linkage of 17864 to 
ULS or ULS-lysozyme even resulted in a stronger inhibitory 
effect of the kinase inhibitor.
In vitro cytotoxicity
As shown in Figure 4, the non-cell-specific multitargeted 
kinase inhibitor sunitinib malate reduced the cell viability 
of HK-2 cells in a dose-dependent manner with an IC50 of 
12 µM. In contrast, exposure of HK-2 cells to equimolar 
amounts of 17864-ULS-lysozyme did not result in decreased 
cell viability. The absence of cytotoxic effects observed 
for 17864-ULS-lysozyme is in agreement with previous 
studies performed with another renal-specific conjugate, ie, 
SB202190-ULS-lysozyme, directed against a different profi-
brotic kinase.25 As anticipated, methionine-modified lysozyme 
alone was also non-toxic to HK-2 cells (data not shown).
Pharmacokinetic studies
Figure 5 shows the plasma disappearance curves of 17864-
ULS-lysozyme and sunitinib after a single intravenous injec-
tion of the compounds in mice. Pharmacokinetic parameters 
were calculated by fitting the data to a two-compartment 
model (Table 1). When comparing the plasma data of 17864-
ULS-lysozyme and sunitinib, the most pronounced differences 
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Figure  3  (A)  HK-2  cells  were  incubated  with  10  µM  17864,  17864-ULS, 
methionine-modified lysozyme, 17864-ULS-lysozyme and sunitinib, and with 0.1% 
(v/v) DMSO (control). After 24 hours of incubation, the cells were lysed and ATP 
was  added  to  stimulate  the  phosphorylation  of  tyrosine  kinases.  Western  blot 
analysis was performed to investigate the inhibitory effects of the compounds on 
the phosphorylation of tyrosine kinases. (B) Freshly prepared HK-2 cell lysates 
were spiked with 2 µM 17864, 17864-ULS, and 17864-ULS-lysozyme (two batches) 
and with 0.1% (v/v) DMSO (control). After 30 minutes of incubation, ATP was 
added to stimulate the phosphorylation of tyrosine kinases. Western blot analysis 
was  performed  to  investigate  the  inhibitory  effects  of  the  compounds  on  the 
phosphorylation of tyrosine kinases.
Abbreviations: ATP, adenosine triphosphate; DMSO, dimethyl sulfoxide.
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Figure 5 Plasma disappearance curves of 17864-ULS-lysozyme (A) and sunitinib (B) after a single intravenous injection in mice. Plasma concentrations were expressed as 
the percentage of the dose in the total circulation. The continuous lines represent the data fitted to a nonlinear multi-compartment model.
were observed in the distribution volumes of the compounds. 
The initial distribution volume (V1) of sunitinib was over 
15-fold higher than for 17864-ULS-lysozyme, which reflects 
the different capability of a small-molecule drug versus a 
hydrophilic macromolecular conjugate to penetrate into cells 
and tissues, as well as the binding of free sunitinib to proteins 
in plasma and tissues.10 Distribution of 17864-ULS-lysozyme 
will be restricted to the circulation and the extracellular fluids, 
as it cannot passively diffuse across membranes. The plasma 
elimination rate of 17864-ULS-lysozyme is in agreement with 
results obtained in earlier studies with other kinase inhibitor-
ULS-lysozyme conjugates.23–25 Furthermore, no free 17864 
could be detected in the circulation after administration of 
17864-ULS-lysozyme, confirming the stability of this type 
of drug–protein conjugate.
Internalization of 17864-ULS-lysozyme into proximal 
tubular cells of the kidneys was demonstrated by immunohis-
tochemical staining of the lysozyme part of the conjugate and 
double staining of the internalizing megalin receptor on the 
apical membrane of proximal tubular cells (Figure 6A). Uptake 
of 17864-ULS-lysozyme into the proximal tubular cells was 
observed within 10 minutes after intravenous   administration. 
The observation that internalized 17864-ULS-lysozyme was 
localized in close proximity of the megalin receptor indicates 
that the internalization was still ongoing at this time point. At 
1 hour and 4 hours after administration, further processing of 
17864-ULS-lysozyme in perinuclear vesicles was observed, 
with less intense staining of the conjugate at the luminal brush 
border. Lastly, at 24 hours postinjection, the accumulated 
17864-ULS-lyszoyme was intracellularly degraded, as could 
be observed from the disappearance of the carrier protein 
in the immunostained sections. These data are in line with 
results obtained in earlier studies with a similarly prepared 
imatinib-ULS-lysozyme conjugate.40
We also analyzed the renal drug levels after intrave-
nous injection of 17864-ULS-lysozyme and sunitinib 
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Table 1   Pharmacokinetic  parameters  of  17864-ULS-lysozyme 
and sunitinib derived from the plasma disappearance curves after 
a single intravenous injection
Pharmacokinetic parameter 17864-ULS- 
lysozyme
Sunitinib
Initial distribution volume (V1) 2.5 mL 44 mL
Peripheral distribution volume (V2) 7.3 mL 87 mL
Initial half-life (t1/2)α 4 minutes 0.5 minutes
Terminal half-life (t1/2)β 3.3 hours 25 minutes
malate   (Figure 6B). Data were fitted with a nonlinear 
  two-  compartment model and the pharmacokinetic para-
meters of the renal data are summarized in Table 2. Both 
17864-ULS-lysozyme and sunitinib were rapidly taken 
up in the kidneys with short absorption half-lives. Maxi-
mum renal levels of 6.3% and 4.9% of the injected dose 
were reached within 30 minutes after administration of 
17864-ULS-lysozyme and sunitinib, respectively. Com-
paring the renal residence time of   17864-ULS-lysozyme 
with the renal residence time of sunitinib, the renally 
targeted conjugate showed a drastically prolonged renal 
retention. The renal elimination half-life of sunitinib 
was 66 minutes, while 17864-ULS-lysozyme provided 
renal drug levels that lasted for several days and decayed 
with an elimination half-life of 28 hours. Renal levels of 
17864 were still detectable at the end of the experimental 
period, ie, 3 days after administration of the conjugate. As 
reflected in the renal AUC of the compounds, the renal 
drug exposure was increased 28-fold after administration of 
17864-ULS-lysozyme (261% dose*h versus 9.4% dose*h 
for 17864-ULS-lysozyme versus sunitinib, respectively). 
Figure 6C shows that more than 95% of the multitargeted 
kinase inhibitor 17864 detected in the kidneys was present 
in the more active ULS-bound form.
The observations that sunitinib was rapidly eliminated 
from the kidneys can be explained by the presence of 
efflux transporters on the proximal tubular cell membranes. 
  Sunitinib is a substrate of the broad spectrum efflux trans-
porters P-glycoprotein (P-gp) and ATP-binding cassette sub-
family G member 2 ABCG2, both expressed on the apical 
membrane of the proximal tubular cells.41,42 It is reasonable 
to assume that slightly modified derivatives of sunitinib, such 
as 17864, also are substrates of these transporters, while the 
structural features of the platinum adduct make 17864-ULS 
a poor substrate for these efflux transporters. The sustained 
intracellular retention of 17864-ULS may, however, also 
be explained by other differences between the administered 
compounds. Firstly, the platinum group of 17864-ULS is 
charged and the platinum complex will thus have a low 
tendency to diffuse across membranes. Lastly, another fea-
ture that may be involved is the capability of 17864-ULS to 
bind to intracellular proteins or macromolecules, and such 
platinum adducts will not easily be excreted into the urine 
or into the renal interstitium.
Antifibrotic activity of sunitinib and 
17864-ULS-lysozyme in renal fibrosis
Inhibitory effects on the activation of PDGFR-β
Antifibrotic effects of the multikinase inhibitors were 
  studied in mice with UUO-induced tubulointerstitial 
  fibrosis.43 We used mice that had suffered from 3 days’ 
ureteral obstruction, ie, the early stages of renal fibrosis. 
The kidneys of these animals showed all the signs of early 
  fibrosis as indicated by the mild increase in PDGFR-β 
activation and increased deposition and production of 
  profibrotic factors involved in inflammation, EMT and 
ECM. The activity of 17864-ULS-lysozyme was compared 
with the inhibitory effects obtained with a low dosage (ie, 
a single dose equimolar to the conjugate) and a therapeutic 
dosage (ie, 50 mg/kg daily) of sunitinib malate. The thera-
peutic dosage was based on the normal dosage used in cancer 
treatment and was comparable with the dosage used for the 
investigation of the antifibrotic effects of sunitinib malate 
in the treatment of liver cirrhosis (ie, 40 mg/kg daily).17,44 
Internalization of 17864-ULS-lysozyme by the renal proxi-
mal tubular cells is only possible when the conjugate is 
able to reach the megalin receptor on the   apical membrane 
of the cells. In this model for tubulointerstitial fibrosis, 
the urinary flow of the diseased kidney was   disturbed, 
which negatively influenced the renal accumulation of 
  17864-ULS-lysozyme. Therefore, the intravenous injec-
tions of   17864-ULS-lysozyme, low dose sunitinib malate, 
and the first intraperitoneal injection of the high dose suni-
tinib malate were administered 1 hour prior to induction 
of UUO. The second and third intraperitoneal injections of 
50 mg/kg sunitinib malate were administered at 24 hours 
and 48 hours after UUO-induction, respectively.
In the group treated with the therapeutic dosage of suni-
tinib, three mice had to be withdrawn from the experiment 
after the second intraperitoneal injection (day 2), due to drug-
related systemic toxicity. No adverse events were observed 
in the other groups.
As a first readout of the fibrotic responses in the kidney 
after ureteral obstruction, we investigated the levels of 
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Figure 6 (A) Colocalization of 17864-ULS-lysozyme (anti-LZM staining, red color) and the proximal tubular cell-specific internalizing megalin receptor (green color) at 10 
minutes and 1, 4, and 24 hours after intravenous administration of a single dose of 20 mg/kg 17864-ULS-lysozyme. An untreated mouse has been used as control. Symbols in 
the figure represent the tubular lumen (square), the tubulointerstitial space (circle), and the intracellular compartment of the proximal tubular cells (arrow). (B) Comparison 
of total renal 17864 levels after a single intravenous injection of 17864-ULS-lysozyme and renal sunitinib levels after a single intravenous injection of sunitinib malate. The 
increase in AUC obtained with 17864-ULS-lysozyme is highlighted in gray. The continuous lines represent the data fitted to a nonlinear two-compartment model. (C) 
Percentage of the total renal 17864 levels present in the more active 17864-ULS-X form. The average was taken of the mice sacrificed between 0 and 4 hours and sacrificed 
at 24, 48, and 72 hours, respectively.
Table 2   Pharmacokinetic  parameters  of  17864-ULS-lysozyme 
and sunitinib derived from the renal accumulation curves after a 
single intravenous injection
Pharmacokinetic  
parameter
17864-ULS-lysozyme Sunitinib
(t1/2)absorption 3 minutes 4 minutes
(t1/2)elimination 28 hours 66 minutes
Cmax (% of the dose) 6.3% 4.9%
AUC0–∞ 261% dose*hours 9.4% dose*hours
Abbreviations: t1/2, half-life; Cmax, maximal concentration; AUC, area under the curve.
activated PDGFR-β tyrosine kinase. Western blot analysis 
of the p-PDGFR-β levels in the renal cortex demonstrated 
a mild increase in the activation of PDGFR-β after 3 days 
of ureteral obstruction (Figure 7A). Daily treatment with 
high-dose sunitinib resulted in decreased p-PDGFR-β levels 
in the renal cortex, as compared with the non-treated mice 
with UUO-induced renal fibrosis. However, no inhibitory 
effects were observed for 17864-ULS-lysozyme and the low 
dose sunitinib (Figure 7B).
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Inhibitory effects on downstream  
profibrotic factors
As a more downstream readout of profibrotic responses, we 
evaluated the renal mRNA expression levels of collagen 1A2, 
PAI-1, and fibronectin (involved in ECM production) and 
MCP-1 (involved in inflammatory response) in the kidneys. 
Earlier experiments in animals with UUO-induced tubuloint-
erstitial fibrosis have demonstrated the upregulation of these 
factors in this animal model.24,45,46 Indeed, the mRNA expres-
sion levels of collagen 1A2, PAI-1, fibronectin, and MCP-1 in 
the kidneys were significantly elevated in mice with 3 days’ 
UUO compared with normal mice (Figure S1). No inhibi-
tory effects on the elevated mRNA expression levels of the 
profibrotic genes, however, were obtained with 17864-ULS-
lysozyme and the low-dose sunitinib. Mice with UUO-induced 
tubulointerstitial fibrosis treated with a daily intraperitoneal 
injection of high-dose sunitinib had significantly lower renal 
mRNA levels of collagen 1A2 and fibronectin. Renal mRNA 
expression levels were also investigated in renal cortex homo-
genate, in addition to their analysis in total renal homogenate. 
These analyses provided similar trends in renal expression of 
the investigated genes (data not shown).
Renal deposition of α-SMA, collagen IV, and vimentin 
in paraffin-embedded kidney sections was investigated by 
immunostaining (Figure S2). Daily treatment with 50 mg/kg 
sunitinib malate decreased the deposition of vimentin in 
the kidneys, although these differences were not signifi-
cant when quantified by morphometric analysis. Treatment 
with 17864-ULS-lysozyme and low-dose sunitinib did 
not affect the elevated expression levels observed after 
ureter obstruction.
Daily treatment with a high dose of sunitinib resulted in 
a reduction of some of the studied markers, indicating that 
this multitargeted kinase inhibitor may be beneficial for the 
treatment of renal fibrosis. The drug-related toxicity observed 
in this group, however, underscores the need for a more 
focused delivery of the drug to diseased tissues, as undertaken 
in this study. As anticipated, the single low sunitinib dose 
showed no therapeutic benefit. Our pharmacokinetic study 
showed that sunitinib was almost completely eliminated 
from the kidneys within 12 hours after administration, which 
explains the lack of efficacy at 3 days after administration. 
The absence of therapeutic responses following 17864-ULS-
lysozyme treatment were, however, less expected since 
active 17864-ULS metabolites could still be detected in the 
kidneys 3 days after injection. We recently demonstrated the 
capability of 17864-ULS-lysozyme and its metabolites to 
inhibit PDGFR-β kinase.32 There may be several explanations 
for the observed lack of efficacy of 17864-ULS-lysozyme. 
First, the inhibitor levels reached within the target cells may 
have been too low. Treatment with a higher dose or repeated 
doses of 17864-ULS-lysozyme may overcome this problem. 
The dose used in the current study (ie, 40 mg/kg/dose) was 
chosen based on the maximum solubility and injection 
volume of the conjugate that can be tolerated by mice after 
intravenous injection without overloading the systemic circu-
lation. Furthermore, the treatment of mice in this model with 
17864-ULS-lysozyme was limited to a single dose, since the 
obstruction of the ureter prevents the necessary transport of 
the conjugate to the apical side of the proximal tubular cells. 
One of the possibilities to overcome this problem would be 
to investigate the efficacy of 17864-ULS-lysozyme in a UUO 
model in which the obstruction is reversed after inducing 
renal fibrosis. It has however been reported that restoration 
of the ureter can be cumbersome due to adhesions of the 
tissue around the ligature; the inner walls of the ureter can 
stay attached to each other thereby preventing the neces-
sary recovery of the urinary flow. This can be improved by 
clamping the ureter and subsequently replacing the clip every 
2 days to prevent the inner walls of the ureter from merging,47 
or by using an alternative strategy in which the obstructed 
ureter is replaced by the   contralateral (healthy) kidney.48 
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Figure 7 Western blot analysis of activated PDGFR-β (p-PDGFR-β) levels in the renal cortex. (A) Three days ureteral obstruction resulted in an increased activation of 
PDGFR-β tyrosine kinase. (B) Inhibitory effects were only obtained with daily intraperitoneal injections of 50 mg/kg sunitinib malate.
Abbreviations: PDGFR, platelet-derived growth factor receptors; UUO, unilateral ureteral obstruction.
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
428
Dolman et alInternational Journal of Nanomedicine 2012:7
Currently, both methods to reverse the ureter obstruction 
are still in the developmental stage and further validation 
is needed to obtain a reproducible model, representative of 
tubulointerstitial fibrosis in human. As an alternative to the 
UUO model, renal disease models like the unilateral renal 
ischemia-reperfusion (I/R) model25 and diabetic nephropathy 
model49 can be used for studying the efficacy of 17864-ULS-
lysozyme in tubulointerstitial fibrosis. Such models will 
also permit repeated administration of the conjugate, since 
urine flow and proximal tubular reabsorption are not blocked 
by ureter ligation, and have been used by us for testing of 
renally targeted conjugates.23,25 It is advisable, however, to 
demonstrate the therapeutic efficacy of sunitinib in these 
alternative animal models before testing the renally targeted 
conjugate. The potential activity of multikinase inhibitors 
and the required intrarenal dose level is not known at pres-
ent and needs to be investigated prior to efficacy evaluation 
of renally targeted conjugates, similar to the current study 
using the UUO model.
Besides underdosing, several other explanations may be 
given for the lack of efficacy of 17864-ULS-lysozyme in 
the present study. 17864-ULS may not escape easily from 
the lysosomal compartment, where 17864-ULS-lysozyme 
accumulates upon megalin-mediated endocytosis. When the 
charged 17864-ULS metabolites cannot diffuse readily over 
membranes, as discussed above, only free 17864 can reach 
the cytosolic kinases or membrane-bound receptor tyrosine 
kinases. Another explanation for the lack of in vivo efficacy 
may be that high-dose sunitinib exerts its antifibrotic activity 
via other cell types besides proximal tubular cells to coun-
teract fibrosis. Although the proximal tubular cells play a 
pivotal role in the pathogenesis of tubulointerstitial fibrosis, 
peritubular endothelial cells and interstitial fibroblasts are 
also involved.1 Despite the prolonged retention of 17864-
ULS in the kidneys, these cell types will be avoided by the 
drug–lysozyme conjugate. Further investigations in which 
we study the activity of 17864-ULS-lysozyme within the 
kidney after multiple dosing are therefore needed.
Conclusions
In the present study, we investigated the potential use of 
the multikinase inhibitor sunitinib as an antifibrotic agent 
in renal fibrosis. To enhance renal accumulation and 
hence increase the renal selectivity and lower its toxicity, 
a derivative of the multitargeted kinase inhibitor sunitinib 
was developed, ie, 17864. This derivative was conjugated 
to the renal carrier protein lysozyme via the platinum linker 
ULS. The resulting 17864-ULS-lysozyme conjugate and its 
17864-ULS metabolites were active in a multikinase assay. 
Upon   systemic administration in mice, 17864-ULS-lysozyme 
provided sustained levels of ULS-bound 17864 in the kid-
neys. We will evaluate the potential antifibrotic effects of 
this type of renally targeted multikinase inhibitor conjugates 
in models of renal fibrosis that will allow frequent dosing 
of the conjugate, in order to provide intrarenal levels of a 
platinum-bound sunitinib analog without the systemic side 
effects of non-cell specific multikinase inhibitors.
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Figure S1 mRNA expression of collagen 1A2, PAI-1, fibronectin, and MCP-1 in the kidneys. The mRNA levels were determined by qRT-PCR and normalized to the 
household gene TBP. The normalized mRNA expression levels in the kidneys of treated and non-treated mice with UUO were related to the normalized mRNA expression 
levels in the kidneys of control mice (set at 1).
Notes: Data represent the mean +/− SEM. Statistical differences between the non-treated mice with UUO and control mice are indicated as  ♣(P , 0.05). Statistical 
differences between the treated and non-treated mice with UUO are indicated as *(P , 0.05).
Abbreviations: UUO, unilateral ureteral obstruction; qRT-PCR, quantitative reverse transcription polymerase chain reaction; SEM, standard error of the mean.
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Figure S2 Representative microscopic images of paraffin-embedded kidney sections immunostained for α-SMA (A), collagen IV (B), and vimentin (C). In the pathogenesis 
of renal fibrosis α-SMA is involved in EMT of normal epithelial cells into myofibroblasts, collagen IV in ECM production and vimentin in both processes.
Note: The magnification for all images was 20×.
Abbreviations: SMA, smooth muscle actin; EMT, epithelial-to-mesenchymal transition; ECM, extracellular matrix; UUO, unilateral ureteral obstruction.
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